World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ChiCTR
Last refreshed on: 5 October 2020
Main ID:  ChiCTR2000037172
Date of registration: 2020-08-27
Prospective Registration: Yes
Primary sponsor: Shanghai Traditional Chinese Medicine Hospital
Public title: Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease
Scientific title: Randomized Double-blind Controlled Study of Shenshi Shengdiqinlian Tufuling Decoction in the Treatment of Mucocutaneous Behcet's Disease
Date of first enrolment: 2021-01-01
Target sample size: experimental group:60;control group:60;
Recruitment status: Pending
URL:  http://www.chictr.org.cn/showproj.aspx?proj=60030
Study type:  Interventional study
Study design:  Parallel  
Phase:  0
Countries of recruitment
China
Contacts
Name: ChenWeiwei   
Address:  274 Middle Zhijiang Road, Jing'an District, Shanghai, China
Telephone: +86 18116013386
Email: daphneww@126.com
Affiliation:  Shanghai Traditional Chinese Medicine Hospital
Name: ChenWeiwei   
Address:  274 Middle Zhijiang Road, Jing'an District, Shanghai, China
Telephone: +86 18116013386
Email: daphneww@126.com
Affiliation:  Shanghai Traditional Chinese Medicine Hospital
Key inclusion & exclusion criteria
Inclusion criteria: 1. Aged >= 16 years;
2. In compliance with the 2013 International Behets disease diagnostic criteria;
3. The patient or his family members signed the informed consent.

Exclusion criteria: Exclude other autoimmune diseases (systemic lupus erythematosus, Crohns disease, ulcerative colitis), exclude infection-related diseases (syphilis, active Tuberculosis), exclude the tumor.

Age minimum: 16
Age maximum: 70
Gender: Both
Health Condition(s) or Problem(s) studied
Behcet's Disease
Intervention(s)
experimental group:Shen's Qinlian Soil Fuling Granules + Thalidomide Tablets;control group:placebo + Thalidomide Tablets ;
Primary Outcome(s)
Erythrocyte sedimentation rate ;C reactive protein;Interleukin-4;Interleukin-6;Interleukin-10;Tumor necrosis factor Tumor a necrosis factor a;
Secondary Outcome(s)
Secondary ID(s)
ChiMCTR2000003766
Source(s) of Monetary Support
Shanghai Shenkang Hospital Development Center
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Ling Li
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history